Agile Therapeutics FY2023 rev $19.6M (+80% YoY); GAAP net loss $14.5M; Nasdaq delisted; debt paid

AGILE THERAPEUTICS INC

Full year 2023 net revenue $19.6M, up 80% YoY; Twirla demand up 131% to 243,841 cycles.
GAAP net loss $14.5M ($6.71/share); non-GAAP net loss $21.2M ($9.84/share); OPEX down 33% to $30.5M.
Cash $2.5M at Dec 31, 2023; raised $4.8M via warrant exercise in Feb 2024; paid off Perceptive Advisors debt in Q1 2024.
Delisted from Nasdaq on Mar 25; now trading on OTC under AGRX; does not expect impact on business.
Twirla demand rebounding in Q1 2024; January retail cycles (26,464) highest single month since launch.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGILE THERAPEUTICS INC reported the three months and fiscal year ended December 31, 2023 results: revenue Net revenue for the fourth quarter 2023 was $3.6 million.

Period: the three months and fiscal year ended December 31, 2023
Revenue: Net revenue for the fourth quarter 2023 was $3.6 million
Result: reported results

Exact text from the filing

On March 28, 2024, Agile Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months and fiscal year ended December 31, 2023 and an update on the Company’s operations.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001558370-24-004174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.